Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

Meta-analysis of randomized clinical trials comparing short-term versus long-term dual antiplatelet therapy following drug-eluting stents.

El-Hayek G, Messerli F, Bangalore S, Hong MK, Herzog E, Benjo A, Tamis-Holland JE.

Am J Cardiol. 2014 Jul 15;114(2):236-42. doi: 10.1016/j.amjcard.2014.04.035. Epub 2014 May 2.

PMID:
24856318
[PubMed - in process]
2.

Shorter (≤6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: A meta-analysis of randomized clinical trials.

Pandit A, Giri S, Hakim FA, Fortuin FD.

Catheter Cardiovasc Interv. 2014 Apr 18. doi: 10.1002/ccd.25520. [Epub ahead of print]

PMID:
24753084
[PubMed - as supplied by publisher]
3.

Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: a meta-analysis of randomized trials.

Valgimigli M, Park SJ, Kim HS, Park KW, Park DW, Tricoci P, Ferrante G.

Int J Cardiol. 2013 Oct 3;168(3):2579-87. doi: 10.1016/j.ijcard.2013.03.047. Epub 2013 Apr 13.

PMID:
23590932
[PubMed - in process]
4.

Consideration of dual anti-platelet therapy duration after drug-eluting stent implantation in a Japanese population: a five-year follow-up after sirolimus-eluting stent implantation.

Kotani J, Ikari Y, Kyo E, Nakamura M, Yokoi H; J-PMS investigators.

Intern Med. 2013;52(7):703-11. Epub 2013 Apr 1.

PMID:
23545663
[PubMed - indexed for MEDLINE]
Free Article
5.

Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation: A Meta-analysis of 3 Randomized Controlled Trials.

Liu M, Chen J, Huang D, Ke J, Tang W, Wu W.

J Cardiovasc Pharmacol. 2014 Jul;64(1):41-6. doi: 10.1097/FJC.0000000000000088.

PMID:
24566464
[PubMed - in process]
6.

A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).

Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Kang TS, Park BE, Kang WC, Lee SH, Yoon JH, Hong BK, Kwon HM, Jang Y; RESET Investigators.

J Am Coll Cardiol. 2012 Oct 9;60(15):1340-8. doi: 10.1016/j.jacc.2012.06.043. Epub 2012 Sep 19.

PMID:
22999717
[PubMed - indexed for MEDLINE]
Free Article
7.

Optimal duration of dual-antiplatelet therapy following drug-eluting stent implantation: a meta-analysis.

Zhang T, Shen L, Hu L, He B.

J Clin Pharmacol. 2013 Mar;53(3):345-51. doi: 10.1177/0091270012448398. Epub 2013 Jan 24.

PMID:
23444287
[PubMed - indexed for MEDLINE]
8.

Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.

Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, Han KR, Choi JH, Choi SH, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Jang Y, Kim HS.

Circulation. 2012 Jan 24;125(3):505-13. doi: 10.1161/CIRCULATIONAHA.111.059022. Epub 2011 Dec 16.

PMID:
22179532
[PubMed - indexed for MEDLINE]
Free Article
9.

Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.

Musumeci G, Rossini R, Lettieri C, Capodanno D, Romano M, Rosiello R, Guagliumi G, Valsecchi O, Gavazzi A, Angiolillo DJ.

Catheter Cardiovasc Interv. 2012 Sep 1;80(3):395-405. doi: 10.1002/ccd.23337. Epub 2012 Jan 10.

PMID:
22109961
[PubMed - indexed for MEDLINE]
10.

Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.

Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB 3rd, Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ Jr, Nicolela EL Jr, Perin MA, Devito FS, Labrunie A, Salvadori D Jr, Gusmão M, Staico R, Costa JR Jr, de Castro JP, Abizaid AS, Bhatt DL; OPTIMIZE Trial Investigators.

JAMA. 2013 Dec 18;310(23):2510-22. doi: 10.1001/jama.2013.282183.

PMID:
24177257
[PubMed - indexed for MEDLINE]
11.

Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia).

Campo G, Tebaldi M, Vranckx P, Biscaglia S, Tumscitz C, Ferrari R, Valgimigli M.

J Am Coll Cardiol. 2014 Feb 18;63(6):506-12. doi: 10.1016/j.jacc.2013.09.043. Epub 2013 Oct 23.

PMID:
24161321
[PubMed - indexed for MEDLINE]
12.

Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents.

Kandzari DE, Barker CS, Leon MB, Mauri L, Wijns W, Fajadet J, Mehran R.

JACC Cardiovasc Interv. 2011 Oct;4(10):1119-28. doi: 10.1016/j.jcin.2011.06.017.

PMID:
22017938
[PubMed - indexed for MEDLINE]
Free Article
13.

Antiplatelet and Anticoagulant Treatments for Unstable Angina/Non–ST Elevation Myocardial Infarction [Internet].

Melloni C, Jones WS, Washam JB, Hasselblad V, Mayer SB, Halim S, Subherwal S, Alexander K, Kong DF, Heidenfelder BL, Irvine RJ, Wing L, Dolor RJ.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Nov.

PMID:
24308072
[PubMed]
Books & Documents
14.

Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.

Cassese S, Byrne RA, Tada T, King LA, Kastrati A.

Eur Heart J. 2012 Dec;33(24):3078-87. doi: 10.1093/eurheartj/ehs318. Epub 2012 Oct 22. Review.

PMID:
23091199
[PubMed - indexed for MEDLINE]
Free Article
15.

Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY).

Valgimigli M, Borghesi M, Tebaldi M, Vranckx P, Parrinello G, Ferrari R; PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY Investigators.

Eur Heart J. 2013 Mar;34(12):909-19. doi: 10.1093/eurheartj/ehs460. Epub 2013 Jan 12.

PMID:
23315904
[PubMed - indexed for MEDLINE]
Free Article
16.

Dual antiplatelet therapy over 6 months increases the risk of bleeding after biodegradable polymer-coated sirolimus eluting stents implantation: insights from the CREATE study.

Zhang L, Li Y, Jing QM, Wang XZ, Ma YY, Wang G, Xu B, Gao RL, Han YL; CREATE Investigators.

J Interv Cardiol. 2014 Apr;27(2):119-26. doi: 10.1111/joic.12104. Epub 2014 Mar 12.

PMID:
24617336
[PubMed - in process]
17.

Duration of dual antiplatelet therapy after implantation of drug-eluting stents.

Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, Han KH, Park SW, Yun SC, Lee SG, Rha SW, Seong IW, Jeong MH, Hur SH, Lee NH, Yoon J, Yang JY, Lee BK, Choi YJ, Chung WS, Lim DS, Cheong SS, Kim KS, Chae JK, Nah DY, Jeon DS, Seung KB, Jang JS, Park HS, Lee K.

N Engl J Med. 2010 Apr 15;362(15):1374-82. doi: 10.1056/NEJMoa1001266. Epub 2010 Mar 15.

PMID:
20231231
[PubMed - indexed for MEDLINE]
Free Article
18.

Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial.

Helft G, Le Feuvre C, Georges JL, Carrie D, Leclercq F, Eltchaninoff H, Furber A, Prunier F, Sebagh L, Cattan S, Cayla G, Vicaut E, Metzger JP.

Trials. 2013 Feb 21;14:56. doi: 10.1186/1745-6215-14-56.

PMID:
23433461
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.

Yu X, Chen F, He J, Gao Y, Wu C, Luo Y, Zhang X, Zhang Y, Ren X, Lv S.

Coron Artery Dis. 2013 May;24(3):217-23. doi: 10.1097/MCA.0b013e32835c8f74.

PMID:
23425771
[PubMed - indexed for MEDLINE]
20.

Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type.

Camenzind E, Boersma E, Wijns W, Mauri L, Rademaker-Havinga T, Ordoubadi FF, Suttorp MJ, Kurdi MA, Steg PG; on behalf of the PROTECT Steering Committee and Investigators.

Eur Heart J. 2014 Mar 13. [Epub ahead of print]

PMID:
24627416
[PubMed - as supplied by publisher]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk